PanTum® Detect - A multi-tumor screening blood test for asymptomatic healthy individuals
Find tumors before it is too late !

Get screened with PanTum® Detect today
The best cure for cancer is to detect silently growing tumors before they become dangerous
bt_bb_section_bottom_section_coverage_image

The Problem

Cancer is usually detected in late stages

A vast majority of cancers show no symptoms until late stages, when treatment is complex, painful, traumatic, with poor clinical outcomes and high medical costs.

 

https://www.medidect.com/wp-content/uploads/2023/08/Medidect-03.png

^ Diagnostic and treatment cost are estimates based on mapping of private hospital costs with cancer diagnostic & treatment pathways per stage of detection

India’s cancer reality

https://www.medidect.com/wp-content/uploads/2024/01/WHO-Logo-320x180.png
1 in 10 Indians will develop cancer during their lifetime
https://www.medidect.com/wp-content/uploads/2024/01/Picture1-640x135.png

*Source: https://www.hindustantimes.com/india-news/one-in-10-indians-will-develop-cancer-during-their-lifetime-who/story-NcNQhPTS01YWI9Qovfcy5J.html

https://www.medidect.com/wp-content/uploads/2024/01/Indian_Council_of_Medical_Research_Logo.svg_-e1705310373624-320x140.png
1 in 9 Indians will develop cancer during their lifetime
https://www.medidect.com/wp-content/uploads/2024/01/Picture2-640x150.png

*Source: https://www.hindustantimes.com/lifestyle/health/cancer-risk-factors-here-s-why-indians-are-at-a-higher-risk-of-the-disease-101675603191553.html

Cancer is a global killer caused by the silent growth & invasion of malignant tumors across different organs of an individual’s body.

https://www.medidect.com/wp-content/uploads/2024/01/PanTumAsset-3.png

Cancer is a global killer caused by the silent growth & invasion of malignant tumors across different organs of an individual’s body.

In selected countries, regular screening examinations exist for only 6 (3%) out of more than 200 types of cancer known globally.

A large majority of the 1.4 million (per Globocan 2022) new cancer cases each year show up in late-stages (3,4) of cancer.

A large majority of the 1.4 million (per Globocan 2022) new cancer cases each year show up in late-stages (3,4) of cancer.

https://www.medidect.com/wp-content/uploads/2024/06/India-Cancer.jpg
This huge cancer screening gap leads to late-stage detection which is associated with high death rate and high medical costs for payors of cancer treatment costs.
https://www.medidect.com/wp-content/uploads/2024/06/India-Cancer.jpg

The Solution

Introducing multi-tumor screening blood test for asymptomatic healthy individuals

https://www.medidect.com/wp-content/uploads/2023/07/PanTum-Logo.png

PanTum Detect screens healthy adults for dangerous tumors covering all solid cancers

https://www.medidect.com/wp-content/uploads/2024/06/PanTumLab.png

SAFE, ACCURATE AND CLINICALLY PROVEN GERMAN TECHNOLOGY

0123456789001234567890                     .01234567890                     %
Sensitivity*
*Sensitivity: True positives
0123456789001234567890                     %
Specificity*
* Specificity: True negatives
0123456789001234567890                     +
Publications
01234567890                     ,012345678900123456789001234567890                     +
Candidate Studies
012345678900123456789001234567890                     ,012345678900123456789001234567890                     +
Tests performed globally

Introducing Cancer-Scan Program Initiated by pre-testing with PanTum Detect

https://www.medidect.com/wp-content/uploads/2024/01/PanTumAsset-6-640x423.png
Combines pre-testing and targeted follow-up cancer diagnostics only for those screened candidates that test positive with PanTum Detect blood test.

Innovative & Unique

The EDIM technology is backed by science and more than 20 years of research

Leveraging the immune system to deliver high accuracy of PanTum® Detect test

EDIM (Epitope Detected in Monocytes) Technology detects elevated levels of enzyme tumor biomarkers (Apo10 & TKTL-1) in macrophages. It leverages on our innate immune system, wherein macrophages do a biological biopsy and engulf universal enzyme tumor biomarkers (Apo10 & TKTL-1) when they phagocytose degenerated tumor cells.

https://www.medidect.com/wp-content/uploads/2023/04/EDIM1.png
https://www.medidect.com/wp-content/uploads/2023/04/EDIM1.png

Leveraging the immune system to deliver high accuracy of PanTum® Detect test

The human immune system is first to recognize the progression of disease, even before the onset of symptoms. EDIM® (Epitope Detection in Monocytes/Macrophages) technology makes the information contained in the human immune system visible for detection of cancer. Higher than normal levels of Apo10 (DNaseX) & TKTL1 detected in immune cells (macrophages) of screened individuals gives an indication of potential cancer and pre-cancer lesions in early and symptomless stages for healthy individuals.